
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: <em>Gastroenterology</em> 2025;168:267–284 | https://doi.org/10.1053/j.gastro.2024.11.008  </li>
<li style="margin-left: 0px;">Topic: Hepatitis B virus reactivation (HBVr) risk stratification and antiviral prophylaxis  </li>
<li style="margin-left: 0px;">Author(s): Faisal S. Ali, Mindie H. Nguyen, Ruben Hernaez, Daniel Q. Huang, Julius Wilder, Alejandro Piscoya, Tracey G. Simon, Yngve Falck-Ytter  </li>
</ul>
<details><summary><strong>1. Definitions and Risk Stratification Framework  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">HBVr defined as: <em>de novo</em> HBV-DNA detection OR ≥10-fold rise from baseline; permissible surrogates: new HBsAg or HBeAg  </li>
<li style="margin-left: 0px;">Hepatitis flare due to HBVr = <em>ALT ≥3× baseline</em> (minimum above reference range)  </li>
<li style="margin-left: 0px;">Baseline risk of HBVr = reactivation rate in exposed individuals <em>not</em> on prophylaxis  </li>
<li style="margin-left: 0px;">Risk categories: <strong>low (&lt;1%)</strong>, <strong>moderate (1%–10%)</strong>, <strong>high (&gt;10%)</strong>  </li>
</ul>
<details><summary><strong>Key serologic definitions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: current infection  </li>
<li style="margin-left: 0px;"><em>anti-HBc–positive/HBsAg-negative</em>: resolved infection (occult HBV)  </li>
<li style="margin-left: 0px;"><em>anti-HBs–positive</em> status does <strong>not</strong> mitigate reactivation risk  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>2. Evidence on Antiviral Prophylaxis Efficacy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Pooled RR for HBVr with prophylaxis vs monitoring: <strong>0.18 (95% CI, 0.11–0.30)</strong> → <strong>82% relative reduction</strong>  </li>
<li style="margin-left: 0px;">Pooled RR for hepatitis flare: <strong>0.22 (95% CI, 0.10–0.50)</strong> → <strong>72% relative reduction</strong>  </li>
<li style="margin-left: 0px;">Absolute risk reduction scales with baseline risk:  </li>
<li style="margin-left: 20px;"><em>High-risk</em> (e.g., 50% baseline): <strong>410 fewer HBVr cases / 1000</strong>  </li>
<li style="margin-left: 20px;"><em>Moderate-risk</em> (e.g., 5% baseline): <strong>41 fewer HBVr cases / 1000</strong>  </li>
<li style="margin-left: 20px;"><em>Low-risk</em> (e.g., 0.1% baseline): <strong>1 fewer HBVr case / 1000</strong>  </li>
</ul>
<details><summary><strong>Evidence certainty  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">High for HBVr prevention: <strong>moderate certainty</strong> (⨁⨁⨁/)  </li>
<li style="margin-left: 0px;">Hepatitis flare: <strong>moderate certainty</strong>  </li>
<li style="margin-left: 0px;">Chemotherapy interruption &amp; adverse events: <strong>very low / low certainty</strong>  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Exposure-Specific Risk Categorization  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>High-risk exposures (baseline risk &gt;10%)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-positive</em> patients receiving:  </li>
<li style="margin-left: 20px;">Anthracyclines (e.g., doxorubicin)  </li>
<li style="margin-left: 20px;">B cell–depleting agents (rituximab, ofatumumab)  </li>
<li style="margin-left: 20px;">Anti–TNF agents (infliximab, adalimumab)  </li>
<li style="margin-left: 20px;">TKIs (e.g., imatinib, sunitinib)  </li>
<li style="margin-left: 20px;">Cytokine/integrin inhibitors (ustekinumab, secukinumab)  </li>
<li style="margin-left: 20px;">CAR-T therapy  </li>
<li style="margin-left: 20px;">Anti-IL6 agents (tocilizumab)  </li>
<li style="margin-left: 20px;">JAK inhibitors (tofacitinib, baricitinib)  </li>
<li style="margin-left: 20px;">TACE for hepatocellular carcinoma  </li>
<li style="margin-left: 20px;">HCV co-infection + DAA therapy  </li>
</ul>
</div></details>
<details><summary><strong>Moderate-risk exposures (baseline risk 1%–10%)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em> patients receiving:  </li>
<li style="margin-left: 20px;">Anthracyclines  </li>
<li style="margin-left: 20px;">ICIs (nivolumab, pembrolizumab, ipilimumab)  </li>
<li style="margin-left: 20px;">Anti–T-cell therapy (abatacept)  </li>
<li style="margin-left: 20px;">TKIs  </li>
<li style="margin-left: 20px;">Cytokine/integrin inhibitors  </li>
<li style="margin-left: 20px;">CAR-T therapy  </li>
<li style="margin-left: 20px;">Anti-IL6 agents  </li>
<li style="margin-left: 20px;">JAK inhibitors  </li>
<li style="margin-left: 20px;">TACE  </li>
<li style="margin-left: 20px;">Corticosteroids: moderate/high dose (≥10–20 mg prednisone eq) for ≥4 weeks  </li>
<li style="margin-left: 0px;"><em>HBsAg-positive</em> patients receiving:  </li>
<li style="margin-left: 20px;">ICIs, anti–T-cell therapy, JAK inhibitors, TACE → <em>high risk</em>  </li>
<li style="margin-left: 20px;">Corticosteroids: low dose (&lt;10 mg) for ≥4 weeks  </li>
</ul>
</div></details>
<details><summary><strong>Low-risk exposures (baseline risk &lt;1%)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>All serologies</em> receiving:  </li>
<li style="margin-left: 20px;">Methotrexate, 6-MP, azathioprine (monotherapy)  </li>
<li style="margin-left: 20px;">Intra-articular steroid injection  </li>
<li style="margin-left: 20px;">Corticosteroids: low/moderate/high dose for &lt;1 week  </li>
<li style="margin-left: 0px;"><em>HBsAg-negative</em> receiving:  </li>
<li style="margin-left: 20px;">Anti–TNF agents  </li>
<li style="margin-left: 20px;">ICIs  </li>
<li style="margin-left: 20px;">HCV co-infection + DAA therapy  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Recommendations and Implementation Guidance  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Recommendation 1: High-risk individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Strong recommendation</strong> for antiviral prophylaxis over monitoring  </li>
<li style="margin-left: 20px;"><em>RR reduction: 82%</em>; NNT ≈ <strong>3</strong> at 50% baseline risk  </li>
<li style="margin-left: 0px;">Implementation:  </li>
<li style="margin-left: 20px;">Use antivirals with <strong>high barrier to resistance</strong> (e.g., entecavir, tenofovir)  </li>
<li style="margin-left: 20px;">Start <em>before</em> immunosuppression; continue ≥6 months post-therapy  </li>
<li style="margin-left: 20px;"><strong>≥12 months</strong> for B cell–depleting agents (risk of delayed reactivation)  </li>
</ul>
</div></details>
<details><summary><strong>Recommendation 2: Moderate-risk individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Conditional recommendation</strong> for antiviral prophylaxis over monitoring  </li>
<li style="margin-left: 20px;"><em>RR reduction: 82%</em>; absolute benefit depends on baseline risk (e.g., 41 fewer / 1000 at 5% baseline)  </li>
<li style="margin-left: 0px;">Monitoring protocol if chosen:  </li>
<li style="margin-left: 20px;"><strong>1- to 3-month intervals</strong>  </li>
<li style="margin-left: 20px;">Must include <em>HBV-DNA</em> + <em>ALT</em>  </li>
<li style="margin-left: 0px;">Shared decision-making encouraged: prioritize patient values on cost, adherence, long-term drug use  </li>
</ul>
</div></details>
<details><summary><strong>Recommendation 3: Low-risk individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Conditional recommendation</strong> for monitoring alone over prophylaxis  </li>
<li style="margin-left: 20px;">Absolute benefit minimal (e.g., 1 fewer / 1000 at 0.1% baseline)  </li>
<li style="margin-left: 0px;">Exceptions: consider prophylaxis if:  </li>
<li style="margin-left: 20px;">Multiple low-risk agents used concurrently  </li>
<li style="margin-left: 20px;">High patient risk aversion despite small benefit  </li>
</ul>
</div></details>
<details><summary><strong>Recommendation 4: Universal HBV Screening  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Strong recommendation</strong> for testing all at-risk individuals  </li>
<li style="margin-left: 20px;">Aligns with CDC universal screening: <em>HBsAg, anti-HBs, total anti-HBc</em> for all ≥18 years  </li>
<li style="margin-left: 20px;">Stratified screening by HBVr risk <strong>no longer needed</strong>  </li>
<li style="margin-left: 0px;">Testing algorithm:  </li>
<li style="margin-left: 20px;">Initial: <em>HBsAg + anti-HBc</em> (minimum)  </li>
<li style="margin-left: 20px;">If positive: add <em>anti-HBs</em> and <em>HBV-DNA</em> as indicated  </li>
<li style="margin-left: 0px;">Note: Antiviral therapy indicated for active HBV regardless of reactivation risk context  </li>
</ul>
<p><em>End of Part 1.</em></p>
</div></details>
</div></details>
<details><summary><strong>5. Duration of Antiviral Prophylaxis  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Pooled analysis of 3 RCTs comparing longer vs shorter prophylaxis duration:  </li>
<li style="margin-left: 20px;"><em>RR for HBVr</em>: <strong>0.99 (95% CI, 0.76–1.28)</strong>  </li>
<li style="margin-left: 20px;"><em>RR for hepatitis flare</em>: <strong>1.24 (95% CI, 0.46–3.39)</strong>  </li>
<li style="margin-left: 0px;">Certainty downgraded to <strong>low</strong> due to serious imprecision (wide CIs crossing null)  </li>
<li style="margin-left: 0px;">Subgroup analysis: 12 vs 6 months post-exposure cessation:  </li>
<li style="margin-left: 20px;"><em>RR for HBVr</em>: <strong>1.07 (95% CI, 0.68–1.68)</strong>  </li>
<li style="margin-left: 20px;"><em>RR for hepatitis flare</em>: <strong>1.35 (95% CI, 0.45–3.99)</strong>  </li>
<li style="margin-left: 0px;">Panel conclusion:  </li>
<li style="margin-left: 20px;">Minimum duration: <strong>≥6 months</strong> after stopping risk-imposing exposure  </li>
<li style="margin-left: 20px;">Extend to <strong>12 months</strong> for high-risk exposures (e.g., B cell–depleting agents, CAR-T)  </li>
<li style="margin-left: 20px;">Special case: HCV/DAA co-infection → extend prophylaxis <strong>6–12 months after DAA completion</strong>, despite early HBVr clearance during therapy (cumulative incidence &gt;90% post-cessation at 12 weeks)  </li>
</ul>
</div></details>
<details><summary><strong>6. Risk-Specific Baseline Estimates by Exposure Class  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Corticosteroid Therapy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Highest risk: <strong>high-dose (≥20 mg prednisone eq/day) for ≥4 weeks</strong> in <em>HBsAg-positive</em>  </li>
<li style="margin-left: 20px;">Baseline risk: <strong>&gt;10% (high-risk)</strong>  </li>
<li style="margin-left: 0px;">Moderate-dose (10–20 mg) for ≥4 weeks in <em>HBsAg-negative/anti-HBc–positive</em>:  </li>
<li style="margin-left: 20px;">Baseline risk: <strong>1%–10% (moderate-risk)</strong>  </li>
<li style="margin-left: 0px;">Low-dose (&lt;10 mg) for ≥4 weeks in <em>HBsAg-negative/anti-HBc–positive</em>:  </li>
<li style="margin-left: 20px;">Baseline risk: <strong>&lt;1% (low-risk)</strong>  </li>
<li style="margin-left: 0px;">Short-course (&lt;1 week) at any dose: <strong>low risk</strong> across serologies  </li>
<li style="margin-left: 0px;">Intra-articular injection: <strong>low risk</strong> regardless of serology  </li>
<li style="margin-left: 0px;">Evidence limitations: confounding by concomitant immunomodulators (e.g., methotrexate); most data indirect  </li>
</ul>
</div></details>
<details><summary><strong>Anti–TNF Agents  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Baseline risk in <em>HBsAg-positive</em>: <strong>332 per 1000 (high-risk)</strong>  </li>
<li style="margin-left: 0px;">Baseline risk in <em>HBsAg-negative/anti-HBc–positive</em>: <strong>2 per 1000 (low-risk)</strong>  </li>
<li style="margin-left: 0px;">Sensitivity analyses: annualized risk ~5–11 per 1000, but nonannualized values reflect worst-case (used for guidance)  </li>
<li style="margin-left: 0px;">No reclassification needed: low-risk category retained for <em>HBsAg-negative/anti-HBc–positive</em>  </li>
</ul>
</div></details>
<details><summary><strong>Immune Checkpoint Inhibitors (ICIs)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: baseline risk <strong>70 per 1000 (moderate-risk)</strong>  </li>
<li style="margin-left: 20px;">Upper 95% CI: <strong>160 per 1000</strong> → crosses high-risk threshold (&gt;100/1000)  </li>
<li style="margin-left: 20px;">Certainty downgraded to <strong>low</strong> due to imprecision  </li>
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em>: baseline risk <strong>&lt;0.1% (low-risk)</strong>  </li>
<li style="margin-left: 20px;">Upper 95% CI: not specified, but panel retained low-risk classification  </li>
<li style="margin-left: 0px;">No stratification by ICI type (nivolumab, pembrolizumab, ipilimumab) due to lack of data  </li>
</ul>
</div></details>
<details><summary><strong>Hepatitis C Virus (HCV)/HBV Co-infection + DAA Therapy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em>: baseline risk <strong>2 per 1000 (low-risk)</strong>  </li>
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: baseline risk <strong>240 per 1000 (high-risk)</strong>  </li>
<li style="margin-left: 0px;">One RCT (entecavir vs monitoring):  </li>
<li style="margin-left: 20px;">No HBVr <em>during</em> DAA therapy  </li>
<li style="margin-left: 20px;"><strong>&gt;90% cumulative incidence</strong> after entecavir cessation at 12 weeks  </li>
<li style="margin-left: 0px;">Panel recommendation: extend prophylaxis <strong>6–12 months post-DAA completion</strong>  </li>
</ul>
</div></details>
<details><summary><strong>Cytokine/Integrin Inhibitors (e.g., ustekinumab, secukinumab)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em>: baseline risk <strong>13 per 1000 (moderate-risk)</strong>  </li>
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: baseline risk <strong>260 per 1000 (high-risk)</strong>  </li>
<li style="margin-left: 0px;">Studies: psoriasis (4), axial spondyloarthritis (1); follow-up 9–24 months  </li>
<li style="margin-left: 0px;">No RCTs for <em>HBsAg-positive</em> on prophylaxis-free arms (clinical practice precludes it)  </li>
</ul>
</div></details>
<details><summary><strong>Anti–IL6 Therapy (Tocilizumab)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em>: baseline risk <strong>&lt;0.1% (low-risk)</strong>  </li>
<li style="margin-left: 20px;">Upper 95% CI: <strong>13 per 1000</strong> → crosses moderate-risk threshold  </li>
<li style="margin-left: 20px;">Certainty downgraded to <strong>low</strong> due to imprecision  </li>
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: no empirical data (all on prophylaxis in clinical practice)  </li>
<li style="margin-left: 20px;">Panel classified as <strong>high-risk</strong> by biological plausibility  </li>
</ul>
</div></details>
<details><summary><strong>Tyrosine Kinase Inhibitors (TKIs)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em>: baseline risk <strong>&lt;0.1% (low-risk)</strong>  </li>
<li style="margin-left: 20px;">Upper 95% CI: <strong>22 per 1000</strong> → suggests true risk ~moderate  </li>
<li style="margin-left: 20px;">Multiple case reports of HBVr in TKI-treated patients  </li>
<li style="margin-left: 20px;">Panel classified as <strong>moderate-risk</strong> (22/1000) despite point estimate &lt;0.1%  </li>
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: baseline risk <strong>110 per 1000 (high-risk)</strong>  </li>
</ul>
</div></details>
<details><summary><strong>Anti–T-Cell Therapy (Abatacept)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em>: baseline risk <strong>46 per 1000 (moderate-risk)</strong>  </li>
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: baseline risk <strong>&lt;0.1% (low-risk)</strong>  </li>
<li style="margin-left: 20px;">Upper 95% CI: <strong>44 per 1000</strong> → suggests true risk ~moderate  </li>
<li style="margin-left: 20px;">Single study (n=34), no events → serious imprecision  </li>
<li style="margin-left: 20px;">Panel classified as <strong>moderate-risk</strong> by biological plausibility  </li>
</ul>
</div></details>
<details><summary><strong>CAR-T Cell Therapy  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em>: baseline risk <strong>21 per 1000 (moderate-risk)</strong>  </li>
<li style="margin-left: 20px;">Confounders: prior B cell–depleting agents (e.g., rituximab), co-interventions  </li>
<li style="margin-left: 20px;">Panel acknowledges additive risk from temporally proximate high-risk exposures  </li>
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: no prophylaxis-free data; classified <strong>high-risk</strong> by biological plausibility  </li>
</ul>
</div></details>
<details><summary><strong>Transarterial Chemoembolization (TACE)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: baseline risk <strong>180 per 1000 (high-risk)</strong>  </li>
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em>: no empirical data; classified <strong>moderate-risk</strong> by biological plausibility  </li>
</ul>
</div></details>
<details><summary><strong>Antimetabolites (Methotrexate, 6-MP, Azathioprine)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Baseline risk: <strong>&lt;1% (low-risk)</strong> for monotherapy  </li>
<li style="margin-left: 20px;">No studies reporting HBVr events  </li>
<li style="margin-left: 20px;">Biological plausibility: minimal impact on antibody responses  </li>
<li style="margin-left: 0px;">Classification is <em>conditional</em> until prospective validation  </li>
</ul>
</div></details>
<details><summary><strong>Janus Kinase (JAK) Inhibitors  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><em>HBsAg-negative/anti-HBc–positive</em>: baseline risk <strong>18 per 1000 (moderate-risk)</strong>  </li>
<li style="margin-left: 0px;"><em>HBsAg-positive</em>: baseline risk <strong>333 per 1000 (high-risk)</strong>  </li>
<li style="margin-left: 0px;">Certainty downgraded to <strong>low</strong> for both due to imprecision (small samples, all from RA trials)  </li>
</ul>
</div></details>
<details><summary><strong>Gut-Specific Anti–T-Cell Therapy (Vedolizumab)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Insufficient evidence: 1 case reported in <em>HBV carrier</em> on vedolizumab + corticosteroids + azathioprine  </li>
<li style="margin-left: 0px;">Risk categorization <strong>not possible</strong> pending further data  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>7. Cost-Effectiveness and Equity Considerations  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Cost-Effectiveness Analysis (CEA)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Fujita et al. 2022 CEA: moderate-risk exposure (6% baseline HBVr)  </li>
<li style="margin-left: 20px;">Incremental cost-effectiveness ratio: <strong>US$132,048/QALY</strong>  </li>
<li style="margin-left: 20px;">Willingness-to-pay threshold: <strong>US$45,662/QALY</strong>  </li>
<li style="margin-left: 0px;">Limitation: assumed prophylaxis arm HBVr risk = 2.1% (should be ~1.1% given</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Antiviral Prophylaxis Safety Profile and Harms  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Overall undesirable consequences considered <strong>small or trivial</strong> in benefit–harm balance  </li>
<li style="margin-left: 0px;">Tenofovir disoproxil fumarate (TDF):  </li>
<li style="margin-left: 20px;">Concerns: renal dysfunction, ↓ bone mineral density  </li>
<li style="margin-left: 20px;">Overall effect: <strong>small to trivial</strong>  </li>
<li style="margin-left: 0px;">Tenofovir alafenamide (TAF):  </li>
<li style="margin-left: 20px;">No adverse impact on renal function or bone density vs TDF  </li>
<li style="margin-left: 0px;">Insurance coverage: generally covered, but out-of-pocket costs may act as barrier to adherence  </li>
</ul>
</div></details>
<details><summary><strong>9. Role of Hepatitis B Surface Antibody (anti-HBs) Status  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Pooled proportion of anti-HBs–positive patients in control arms of RCTs: <strong>65% (95% CI, 58%–72%)</strong>  </li>
<li style="margin-left: 0px;">Meta-analysis of RCTs + nonrandomized studies (rituximab cohort):  </li>
<li style="margin-left: 20px;">Baseline risk for <em>anti-HBs–positive</em> individuals: <strong>6.6%</strong>  </li>
<li style="margin-left: 20px;">Upper 95% CI: <strong>14.4%</strong>  </li>
<li style="margin-left: 0px;">Panel conclusion: anti-HBs positivity <strong>does not mitigate HBVr risk</strong>  </li>
<li style="margin-left: 20px;">Therefore, anti-HBs status should <strong>not guide prophylaxis decisions</strong>  </li>
</ul>
</div></details>
<details><summary><strong>10. Knowledge Gaps and Future Research Priorities  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Critical gaps:  </li>
<li style="margin-left: 20px;">Need for prospective registries with standardized HBV serology, clear HBVr definition, and large nonselective cohorts  </li>
<li style="margin-left: 20px;">Uncertainty in risk categorization for newer agents (e.g., gut-specific anti–T cell agents, novel JAK inhibitors) due to lack of data  </li>
<li style="margin-left: 20px;">Long-term reactivation risk beyond 12 months post-exposure cessation (e.g., CAR-T, B cell–depleting agents)  </li>
<li style="margin-left: 0px;">Technological opportunities:  </li>
<li style="margin-left: 20px;">Online repository updated periodically with baseline risk estimates by exposure class  </li>
<li style="margin-left: 20px;">Integration into clinical decision support tools (e.g., EHR-based alerts)  </li>
<li style="margin-left: 0px;">Need for formal cost-effectiveness analyses stratified by risk category (low, moderate, high)  </li>
<li style="margin-left: 0px;">Priority areas for future RCTs:  </li>
<li style="margin-left: 20px;">Duration optimization (e.g., 6 vs 12 months) in specific high-risk groups  </li>
<li style="margin-left: 20px;">Head-to-head comparisons of antivirals (e.g., TAF vs entecavir) in prophylaxis  </li>
<li style="margin-left: 20px;">Real-world adherence and outcomes with monitoring-only strategies  </li>
</ul>
</div></details>
<details><summary><strong>11. Limitations of Current Evidence  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Serious imprecision</strong> in baseline risk estimates for several exposures:  </li>
<li style="margin-left: 20px;">ICIs (<em>HBsAg-positive</em>): upper 95% CI crosses high-risk threshold  </li>
<li style="margin-left: 20px;">Anti-IL6 (<em>HBsAg-negative/anti-HBc–positive</em>): upper 95% CI crosses moderate-risk threshold  </li>
<li style="margin-left: 20px;">TKI (<em>HBsAg-negative/anti-HBc–positive</em>): no events, upper CI suggests moderate risk  </li>
<li style="margin-left: 20px;">Abatacept (<em>HBsAg-positive</em>): very small sample (n=34), CI crosses risk thresholds  </li>
<li style="margin-left: 0px;"><strong>Indirect evidence</strong> for corticosteroids: confounding by concomitant immunomodulators  </li>
<li style="margin-left: 0px;"><strong>Lack of RCTs</strong> for many exposures (e.g., vedolizumab, CAR-T in <em>HBsAg-positive</em> without prophylaxis)  </li>
<li style="margin-left: 0px;"><strong>Publication bias</strong>: potential underreporting of low-event-rate HBVr cases  </li>
<li style="margin-left: 0px;"><strong>Heterogeneity in HBVr definition</strong>:  </li>
<li style="margin-left: 20px;">Some RCTs use absolute HBV-DNA cutoff (e.g., ≥2000 IU/mL)  </li>
<li style="margin-left: 20px;">Some define hepatitis flare as ALT &gt;100 IU/L (vs guideline’s ≥3× baseline)  </li>
<li style="margin-left: 20px;">Panel accepted deviations if clinically reasonable  </li>
</ul>
</div></details>
<details><summary><strong>12. Implementation Considerations and Clinical Decision Support  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Clinical decision support tool</strong> referenced in guideline (Figure 2):  </li>
<li style="margin-left: 20px;">Integrates serologic status + exposure type → risk category → recommendation  </li>
<li style="margin-left: 0px;"><strong>Key implementation principles</strong>:  </li>
<li style="margin-left: 20px;">Universal HBV screening (per CDC) eliminates need for risk-stratified screening  </li>
<li style="margin-left: 20px;">Antiviral choice: high barrier to resistance (entecavir, tenofovir)  </li>
<li style="margin-left: 20px;">Monitoring protocol: mandatory <em>HBV-DNA</em> + <em>ALT</em> at 1–3 month intervals if prophylaxis deferred  </li>
<li style="margin-left: 0px;"><strong>Shared decision-making triggers</strong>:  </li>
<li style="margin-left: 20px;">Moderate-risk patients: discuss tradeoffs between prophylaxis burden vs reactivation risk  </li>
<li style="margin-left: 20px;">Low-risk patients: emphasize minimal absolute benefit but acknowledge individual risk aversion  </li>
<li style="margin-left: 0px;"><strong>Special populations</strong>:  </li>
<li style="margin-left: 20px;"><em>HCV/HBV co-infection</em>: extend prophylaxis beyond DAA course (6–12 months post-DAA)  </li>
<li style="margin-left: 20px;"><em>CAR-T or B cell–depleting therapy</em>: extend prophylaxis to 12 months  </li>
<li style="margin-left: 20px;"><em>Corticosteroid bursts (&lt;1 week)</em>: low risk regardless of serology; no prophylaxis needed  </li>
<li style="margin-left: 0px;"><strong>Follow-up triggers</strong>:  </li>
<li style="margin-left: 20px;">If HBV-DNA rises ≥10-fold or new HBsAg: initiate antivirals immediately  </li>
<li style="margin-left: 20px;">If ALT ≥3× baseline + detectable HBV-DNA: treat as hepatitis flare due to HBVr  </li>
<li style="margin-left: 0px;"><strong>Documentation requirements</strong>:  </li>
<li style="margin-left: 20px;">Baseline serology (HBsAg, anti-HBc, anti-HBs) before immunosuppression  </li>
<li style="margin-left: 20px;">Baseline HBV-DNA if anti-HBc–positive or HBsAg-positive  </li>
<li style="margin-left: 20px;">Plan for monitoring schedule or prophylaxis duration documented at initiation  </li>
</ul>
</div></details>
<details><summary><strong>13. Guideline Development Methodology and Evidence Grading  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>GRADE framework</strong> applied throughout:  </li>
<li style="margin-left: 20px;">Risk of bias assessed via Cochrane RoB 2.0 for RCTs  </li>
<li style="margin-left: 20px;">Certainty of evidence rated across domains: bias, inconsistency, indirectness, imprecision, publication bias  </li>
<li style="margin-left: 0px;"><strong>Evidence profiles</strong> generated for: HBVr, hepatitis flare, chemotherapy interruption, adverse events  </li>
<li style="margin-left: 0px;"><strong>Pooled relative risks</strong> computed using inverse-variance random-effects model (STATA)  </li>
<li style="margin-left: 0px;"><strong>Baseline risk estimates</strong> from control arms of RCTs or observational studies meeting criteria:  </li>
<li style="margin-left: 20px;">Consecutive at-risk cohort not on prophylaxis  </li>
<li style="margin-left: 20px;">Defined HBVr/hepatitis flare criteria aligned with panel consensus  </li>
<li style="margin-left: 20px;">Reported follow-up duration  </li>
<li style="margin-left: 0px;"><strong>Meta-analysis of proportions</strong>: Freeman-Tukey double arcsine transformation for variance stabilization (fixed-effects model)  </li>
<li style="margin-left: 0px;"><strong>Class effect assumption</strong>: risk estimates applied to entire drug class, not just studied agents  </li>
<li style="margin-left: 0px;"><strong>Panel consensus process</strong>: Evidence-to-Decision framework used to weigh:  </li>
<li style="margin-left: 20px;">Certainty of evidence  </li>
<li style="margin-left: 20px;">Balance of desirable/undesirable effects  </li>
<li style="margin-left: 20px;">Patient values and preferences  </li>
<li style="margin-left: 20px;">Feasibility, acceptability, cost-effectiveness, equity  </li>
</ul>
</div></details>
<details><summary><strong>14. Recommendations Summary Table (Expanded)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Recommendation 1: High-risk individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Strong recommendation</strong> for antiviral prophylaxis over monitoring  </li>
<li style="margin-left: 20px;">Evidence: 12 RCTs, <em>n</em> = 879  </li>
<li style="margin-left: 20px;">RR for HBVr: <strong>0.18 (0.11–0.30)</strong>  </li>
<li style="margin-left: 20px;">Absolute risk reduction: <strong>410 fewer / 1000</strong> at 50% baseline  </li>
<li style="margin-left: 0px;">Implementation:  </li>
<li style="margin-left: 20px;">High-barrier antivirals (entecavir, tenofovir)  </li>
<li style="margin-left: 20px;">Start <em>before</em> immunosuppression; continue ≥6 months post-therapy  </li>
<li style="margin-left: 20px;">Extend to <strong>12 months</strong> for B cell–depleting agents (e.g., rituximab, ofatumumab)  </li>
<li style="margin-left: 20px;">Consider CAR-T: ≥12 months due to delayed reactivation cases  </li>
</ul>
</div></details>
<details><summary><strong>Recommendation 2: Moderate-risk individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Conditional recommendation</strong> for antiviral prophylaxis over monitoring  </li>
<li style="margin-left: 20px;">RR reduction: 82%  </li>
<li style="margin-left: 20px;">Absolute benefit: <strong>41 fewer / 1000</strong> at 5% baseline  </li>
<li style="margin-left: 0px;">Monitoring protocol if chosen:  </li>
<li style="margin-left: 20px;">Frequency: <strong>1–3 months</strong>  </li>
<li style="margin-left: 20px;">Mandatory tests: <em>HBV-DNA</em> + <em>ALT</em>  </li>
<li style="margin-left: 0px;">Shared decision-making emphasized:  </li>
<li style="margin-left: 20px;">Patient preference for avoiding long-term antivirals vs fear of reactivation (especially <em>HBsAg-negative</em>)  </li>
<li style="margin-left: 20px;">Feasibility of adherence to long-term lab monitoring  </li>
</ul>
</div></details>
<details><summary><strong>Recommendation 3: Low-risk individuals  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Conditional recommendation</strong> for monitoring alone over prophylaxis  </li>
<li style="margin-left: 20px;">Absolute benefit: <strong>1 fewer / 1000</strong> at 0.1% baseline  </li>
<li style="margin-left: 0px;">Exceptions: consider prophylaxis if:  </li>
<li style="margin-left: 20px;">Multiple low-risk immunosuppressants used concurrently (e.g., methotrexate + corticosteroids)  </li>
<li style="margin-left: 20px;">Patient values prioritize minimal reactivation risk despite trivial benefit  </li>
<li style="margin-left: 0px;">Monitoring still recommended even if prophylaxis chosen: baseline viral load helps detect breakthrough  </li>
</ul>
</div></details>
<details><summary><strong>Recommendation 4: Universal HBV Screening  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Strong recommendation</strong> for testing all at-risk individuals  </li>
<li style="margin-left: 20px;">Aligns with CDC universal screening: <em>HBsAg, anti-HBs, total anti-HBc</em> for all ≥18 years  </li>
<li style="margin-left: 20px;">Risk-stratified screening <strong>no longer needed</strong>  </li>
<li style="margin-left: 0px;">Testing algorithm:  </li>
<li style="margin-left: 20px;">Step 1: <em>HBsAg + anti-HBc</em> (minimum)  </li>
<li style="margin-left: 20px;">Step 2: If positive, add <em>anti-HBs</em> and *</li>
</ul>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
